For people with vitiligo and their caregivers
What this page helps you do
If you are between appointments and wondering whether your vitiligo is changing, a simple record can help you show your dermatologist what you have noticed—without making every day a test of whether treatment is working.
- Your task
- Organize the information, priorities, and next review needed for a real-world decision.
- The clinician boundary
- Diagnosis, assessment of activity and body sites, prescribing, monitoring, and personalized treatment decisions belong to a qualified clinician.
What should I keep track of before my follow-up?
Write down what you noticed, where it happened, whether you were able to follow your treatment plan, and any reaction or interruption. Also keep the questions you want answered at your next visit. Bring that history to your dermatologist, who can interpret it with your examination and treatment plan. Evidence Evidence Evidence
Why this item matters
When clinicians review vitiligo care, they may consider where patches are, whether the condition appears active, what treatment has been used, any side effects, and how care is affecting daily life. A short, consistent record can preserve details that are hard to remember later.
How can I take photos that are easier to compare?
When practical, use the same framing, distance, background and ordinary lighting each time, and keep the original date. That reduces obvious differences between photos, but a phone photo still is not a calibrated medical measurement. Evidence Evidence
Why this item matters
Clinical guidance recognizes standardized medical photography as one way to document vitiligo over time. In personal records, repeating the basic setup makes side-by-side review less vulnerable to obvious changes in angle, scale and lighting.
Can I tell from a photo whether my vitiligo is improving or worsening?
Not from a photo alone. A photo can preserve what the camera captured, but it cannot prove that treatment caused a change or reliably separate repigmentation from differences in lighting, season or camera processing. Evidence Evidence
Why this item matters
Clinicians interpret photographs alongside the history, examination and the pattern of change. Repeated images can support that conversation when their limitations stay visible.
What does a VASI score—or another vitiligo score—tell me?
Measures such as the Vitiligo Area Scoring Index, or VASI, give researchers and clinicians a structured way to describe how much skin is affected or how it has changed. A score is not a diagnosis, a universal definition of success, or a reason to change treatment on your own. Evidence Evidence
Why this item matters
Research uses structured outcome measures so groups and time points can be compared more consistently. Different measures may focus on extent, repigmentation, noticeability or quality of life, so the name of a score matters as much as the number.
What else should we discuss besides whether pigment returned?
Bring up new patches, reactions, how hard the plan is to follow, missed or interrupted care, access problems, and whether the plan still fits your priorities. Pigment returning may matter to you, but it is not the only part of care worth reviewing. Evidence Evidence
Why this item matters
Guidelines include quality of life, adverse effects, adherence burden and personal goals in management discussions. This broader view helps separate “nothing changed in the photograph” from “nothing important happened.”
Questions that can change the next decision
- For your clinicianHow will we decide whether this plan still fits my goal?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For your clinicianCan we discuss burden and side effects as well as visible change?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- JAMA Dermatology (Ezzedine K, et al.)Supporting research · not independentIndependence not established
- Published
- 2024-10-30
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports defined research use and psychometric evaluation of facial and total VASI measures and the need to interpret score change in the studied context.
What it does not support
The analysis used sponsor trial data and included AbbVie authors; it does not establish one personally meaningful outcome, validate untrained home scoring or provide a treatment-change rule.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- Journal of the European Academy of Dermatology and VenereologyRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2023-09-25
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- British Journal of Dermatology (Eleftheriadou V, et al.)Regulatory / guideline · independentIndependent source
- Published
- 2022-01-01
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · independentIndependent source
- Published
- 2022-10-01
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports a patient-facing description of clinician diagnosis using history and examination, possible use of a Wood lamp and selected tests, broad treatment categories, variable response and whole-person support.
What it does not support
It is educational context, not primary efficacy evidence, an online diagnostic method or a universal testing checklist.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.